The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives

Frontiers in Immunology

Wenjuan Li¹  Yang Xu²  Xin Liu²  Xuemei Fu³ 

[1] Center for Regenerative and Translational Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China;Division of Biological Sciences, University of California, San Diego, La Jolla, CA, United States;The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China;

关键词: embryonic stem cells;    induced pluripotent stem cells;    cell therapy;    allogeneic immune rejection;    immunogenicity;    immune tolerance;   

DOI  :  10.3389/fimmu.2017.00645

来源: DOAJ

【 摘 要 】

Human embryonic stem cells (hESCs) can undergo unlimited self-renewal and differentiate into all cell types in human body, and therefore hold great potential for cell therapy of currently incurable diseases including neural degenerative diseases, heart failure, and macular degeneration. This potential is further underscored by the promising safety and efficacy data from the ongoing clinical trials of hESC-based therapy of macular degeneration. However, one main challenge for the clinical application of hESC-based therapy is the allogeneic immune rejection of hESC-derived cells by the recipient. The breakthrough of the technology to generate autologous-induced pluripotent stem cells (iPSCs) by nuclear reprogramming of patient’s somatic cells raised the possibility that autologous iPSC-derived cells can be transplanted into the patients without the concern of immune rejection. However, accumulating data indicate that certain iPSC-derived cells can be immunogenic. In addition, the genomic instability associated with iPSCs raises additional safety concern to use iPSC-derived cells in human cell therapy. In this review, we will discuss the mechanism underlying the immunogenicity of the pluripotent stem cells and recent progress in developing immune tolerance strategies of human pluripotent stem cell (hPSC)-derived allografts. The successful development of safe and effective immune tolerance strategy will greatly facilitate the clinical development of hPSC-based cell therapy.

【 授权许可】

Unknown